MarketPulse

theranostics

4 articles
BenzingaBenzinga··Prnewswire

Radnostix Revenue Plunges 27% as Product Recalls, Supply Woes Halt Momentum

Radnostix reports 27% Q1 revenue decline to $2.38M due to recalls and facility shutdowns, but expects recovery after completing facility repairs.
INISrevenue declinefacility expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix Pharmaceuticals to Showcase Next-Gen PSMA Cancer Therapy Portfolio

Telix Pharmaceuticals hosts webinar April 30 discussing next-gen PSMA cancer therapy pipeline, featuring OPTIMAL-PSMA2 trial data on TLX597-Tx candidate.
TLXclinical trialprostate cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Precedence Research

Radiopharmaceuticals Market to Double to $15.21B by 2035 Amid Cancer Surge

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.
LLYCAHNVSLNTHSIEGY+1cancer treatmentradiopharmaceuticals
BenzingaBenzinga··Prnewswire

Radnostix Posts Second-Best Revenue on Strong Calibration Growth, Eyes 2026 Product Launches

Radnostix posts $13.07M revenue, second-best on record, driven by 21% calibration growth and regained DUF6 assets. Two key products launching 2026.
INISrevenue growthfacility expansion